[Skip to Content]

Claim CME

Neurology

Rituximab Infusion Timing, Cumulative Dose, and Hospitalization for COVID-19 in Persons With Multiple Sclerosis in Sweden

Educational Objective
To identify the key insights or developments described in this article

1 Credit CME

JAMA Network Open

Published Online: December 1, 2021

Research Letter

Article Information and Disclosures

Kyla A. McKay, PhD^1,2;

Fredrik Piehl, MD, PhD^1,3;

Simon Englund, MSc⁴;

Anna He, MD^1,2;

Annette Langer-Gould, MD, PhD⁵;

Jan Hillert, MD, PhD¹;

Thomas Frisell, PhD⁴

Author Affiliations

¹Neuro Division, Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden
²Centre for Molecular Medicine, Karolinska University Hospital, Stockholm, Sweden
³The Karolinska University Hospital and Academic Specialist Centre, Stockholm Health Services, Stockholm, Sweden
⁴Clinical Epidemiology Division, Department of Medicine, Solna, Karolinska Institutet, Stockholm, Sweden
⁵Department of Neurology, Los Angeles Medical Center, Southern California Permanente Medical Group, Los Angeles

Read article on JAMA Network

Read Article Claim CME

Claim CME

Sign in to take quiz and track your certificates

Buy This Activity

Article Information

Accepted for Publication: October 5, 2021.

Published: December 1, 2021. doi:10.1001/jamanetworkopen.2021.36697

Open Access: This is an open access article distributed under the terms of the CC-BY License. © 2021 McKay KA et al. JAMA Network Open.

Corresponding Author: Thomas Frisell, PhD, Clinical Epidemiology Division, Department of Medicine, Solna, Karolinska Institutet, T2, Karolinska University Hospital, 171 76 Stockholm, Sweden (thomas.frisell@ki.se).

Author Contributions: Dr McKay had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

Concept and design: McKay, Piehl, Langer-Gould, Frisell.

Acquisition, analysis, or interpretation of data: All authors.

Drafting of the manuscript: McKay, Piehl.

Critical revision of the manuscript for important intellectual content: Piehl, Englund, He, Langer-Gould, Hillert, Frisell.

Statistical analysis: McKay, Langer-Gould, Frisell.

Obtained funding: Piehl, Langer-Gould, Hillert.

Administrative, technical, or material support: Piehl, He, Frisell.

Supervision: Piehl, Hillert.

Conflict of Interest Disclosures: Dr McKay reported receiving research funding from the Swedish Research Council for Health, Working Life and Welfare. Dr Piehl reported receiving grants from Swedish Medical Research Council, County of Stockholm, Merck KGaA, UCB, and Sanofi-Genzyme as well as personal fees from Parexel and Roche outside the submitted work. Dr Hillert reported receiving grants from Biogen, Celgene, Merck KGaA, Novartis, Bristol Myers Squibb, Roche, and Sanofi-Genzyme; personal fees from Biogen, Celgene, Sanofi-Genzyme, Merck KGaA, Novartis, Teva, Janssen, and Sandoz; and research funding from Swedish Research Council and the Swedish Brain Foundation outside the submitted work. Dr Frisell reported receiving research funding from the Swedish Research Council and NEURO Sweden. No other disclosures were reported.

Funding/Support: This study was supported by the Patient-Centered Outcomes Research Institute (PCORI/MS-1511-33196).

Role of the Funder/Sponsor: The funder had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.

AMA CME Accreditation Information

Credit Designation Statement: The American Medical Association designates this Journal-based CME activity activity for a maximum of 1.00  AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to:

1.00 Medical Knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program;;
1.00 Self-Assessment points in the American Board of Otolaryngology – Head and Neck Surgery’s (ABOHNS) Continuing Certification program;
1.00 MOC points in the American Board of Pediatrics’ (ABP) Maintenance of Certification (MOC) program;
1.00 Lifelong Learning points in the American Board of Pathology’s (ABPath) Continuing Certification program; and
1.00 credit toward the CME of the American Board of Surgery’s Continuous Certification program

It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting MOC credit.